{
    "clinical_study": {
        "@rank": "163197", 
        "arm_group": [
            {
                "arm_group_label": "erlotinib combine with chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Drug: gemcitabine 1000mg/m2 iv on days 1  of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib[Tarceva] po on days 15-28 of each 4 week cycle until disease progression"
            }, 
            {
                "arm_group_label": "erlotinib along", 
                "arm_group_type": "Active Comparator", 
                "description": "Drug: erlotinib [Tarceva] 150mg/day po  until disease progression"
            }
        ], 
        "brief_summary": {
            "textblock": "This 2 arm study will compare the efficacy and safety of treatment with  erlotinib\n      intercalated with platinum-based therapy or  erlotinib along, as first line treatment in\n      Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor\n      (EGFR) Mutation. Patients will be randomized to receive gemcitabine (1000mg/m2 iv) on days 1\n      , and cisplatin (75mg/m2) or carboplatin (5xAUC)on day 1, followed by erlotinib 150mg/day\n      from day 15 to day 28 of each 4 week cycle for a total of 6 cycles,then followed by\n      erlotinib  monotherapy, or erlotinib 150mg/day .The anticipated time on study treatment is\n      until disease progression, and the target sample size is 60 individuals."
        }, 
        "brief_title": "Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients, >=18 years of age;advanced (stage IIIB/IV)non-small cell lung\n             cancer;measurable disease;ECOG Performance Status 0-2.\n\n        Exclusion Criteria:\n\n          -  prior exposure to agents directed at the HER axis;prior chemotherapy or systemic\n             anti-tumor therapy after advanced disease;unstable systemic disease; any other\n             malignancy within last 5 years, except cured basal cell cancer of skin or cured\n             cancer in situ of cervix."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001896", 
            "org_study_id": "XJTHLC001"
        }, 
        "intervention": [
            {
                "arm_group_label": "erlotinib combine with chemotherapy", 
                "intervention_name": "gemcitabine; cisplatin or carboplatin; erlotinib", 
                "intervention_type": "Drug", 
                "other_name": "tarceva"
            }, 
            {
                "arm_group_label": "erlotinib along", 
                "intervention_name": "erlotinib", 
                "intervention_type": "Drug", 
                "other_name": "tarceva"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Carboplatin", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NSCLC", 
            "EGFR-TKI"
        ], 
        "lastchanged_date": "November 28, 2013", 
        "location": {
            "contact": {
                "email": "shanlinew319@163.com", 
                "last_name": "Li Shan, Master", 
                "phone": "13609989394"
            }, 
            "facility": {
                "address": {
                    "city": "Urumqi", 
                    "country": "China", 
                    "state": "Xinjiang", 
                    "zip": "XJTHLC001"
                }, 
                "name": "Xinjiang medical university"
            }, 
            "investigator": {
                "last_name": "Qiang Wang, Master", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label Phase III Study of First-line Treatment With Erlotinib Intercalated With Gemcitabine/ Cisplatin or Carboplatin Therapy Versus Erlotinib in Stage IIIB/IV NSCLC Patients With EGFR Mutation", 
        "overall_contact": {
            "email": "shanlinew319@163.com", 
            "last_name": "Li Shan, Master", 
            "phone": "13609989394"
        }, 
        "overall_contact_backup": {
            "last_name": "Qiang Wang, Master", 
            "phone": "13579960434"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001896"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Xinjiang Medical University", 
            "investigator_full_name": "li shan", 
            "investigator_title": "chief physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of death from any cause,  assessed up to 24 mont"
        }, 
        "source": "Xinjiang Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xinjiang Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}